10 stories
GLP-1 Pricing Deal, Retatrutide Phase 3, Peptide Safety Investigations
Landmark GLP-1 pricing drops to $245/mo, Lilly's retatrutide aces Phase 3, and investigations expose peptide quality failures and safety risks.
Read digest →All Digests
10 stories
Pinnacle Medicines $89M for Oral Peptides, Cagrilintide Phase 3 Monotherapy Results, Higher-Dose Wegovy 21% Weight Loss
Pinnacle raises $89M for oral peptides matching biologics, cagrilintide shows Phase 3 obesity results, and higher-dose Wegovy achieves 21% weight loss.
Read digest → 10 stories
MHRA Peptide Clinic Probe, GLP-1 Price War, Orforglipron Approval
UK MHRA investigates peptide clinics, GoodRx matches oral semaglutide pricing, FDA approves Eli Lilly oral GLP-1, and India tightens GLP-1 oversight.
Read digest → 10 stories
RFK Jr. Peptide Ban Reversal, Retatrutide Phase 3 Results, Oral Semaglutide vs Orforglipron
RFK Jr. moves to reverse FDA peptide ban amid safety pushback; Lilly retatrutide hits Phase 3 endpoints; oral semaglutide may outperform orforglipron.
Read digest → 10 stories
Foundayo FDA Approval, Retatrutide TRIUMPH-4 Results, Semaglutide Safety Signal, Health Tech Peptide Bets
Eli Lilly's oral GLP-1 Foundayo approved in record time; retatrutide hits 28.7% weight loss in Phase 3; semaglutide linked to rare skin condition.
Read digest → 10 stories
FDA Approves Orforglipron, GLP-1 Cardiovascular Benefits, India Regulatory Crackdown
FDA approves Eli Lilly's Foundayo, the first small-molecule GLP-1 pill for obesity. GLP-1 drugs show heart and kidney benefits in Type 1 diabetes.
Read digest → 10 stories
FDA Peptide Ban Reversal, GLP-1 Telehealth Crackdown, Novo Nordisk India Price Cuts
FDA expected to lift peptide compounding ban at RFK Jr.'s urging; 30 telehealth firms warned; Novo slashes Ozempic prices in India; UK expands Wegovy prescribing.
Read digest → 10 stories
Retatrutide Clears Fatty Liver in 85% of Patients, Cagrilintide Phase 3 Obesity Data, GLP-1s for Substance Use Disorders
Retatrutide clears fatty liver in 85%+ of patients, cagrilintide posts Phase 3 obesity results, and Lilly investigates GLP-1s for substance use disorders.
Read digest → 10 stories
FDA Meeting on Peptide Supplements Continues, Oral Wegovy OASIS 4 Approval, Guardian Slams RFK Jr. Peptide Push
PBS covers FDA peptide supplement meeting, oral Wegovy approved on OASIS 4 data, and The Guardian editorial slams RFK Jr.'s peptide deregulation.
Read digest → 10 stories
GLP-1 Drugs Reduce Addiction Risk in 600K Veteran Study, ICOTYDE 52-Week Psoriasis Data, Tesamorelin FDA Approval
Landmark study links GLP-1s to reduced addiction risk in 600K+ veterans, J&J's ICOTYDE shows durable psoriasis clearance, and tesamorelin gets new formulation.
Read digest → 10 stories
FDA Historic Meeting on Peptides as Supplements, Stanford Peptide-to-DNA Breakthrough, Skeptic Magazine on RFK Jr. Deregulation
FDA holds first meeting on peptides as supplement ingredients under RFK Jr., Stanford unveils peptide-to-DNA sequencing, and Skeptic Magazine warns of risks.
Read digest → 10 stories
RFK Jr. Signals Deregulation of 14 Peptides, Lilly/Novo MFN Pricing Deals, Orforglipron Beats Oral Semaglutide in ACHIEVE-3
RFK Jr. signals FDA will lift restrictions on ~14 peptides, Lilly and Novo strike MFN pricing deals, and orforglipron outperforms oral semaglutide.
Read digest → 10 stories
Novo Nordisk Slashes US Prices 50%, Retatrutide 28.7% Weight Loss Record, 10-Year GLP-1 Cancer Prevention Trial Proposed
Novo Nordisk cuts US list prices ~50% for 2027, retatrutide hits record 28.7% weight loss in Phase 3, and experts propose 10-year GLP-1 cancer trial.
Read digest → 10 stories
FDA Approves Oral Semaglutide and Higher Ozempic Dose, Survodutide Breakthrough Designation, Cyclic Peptide Oral Insulin Breakthrough
FDA approves oral semaglutide pill and higher Ozempic dose, grants survodutide breakthrough designation for MASH, and oral insulin via cyclic peptides advances.
Read digest → 10 stories
Compounded GLP-1 Prescriptions Surge Despite Crackdown, PeptideSciences Shuts Down, Ozempic Real-World Weight Regain Data
Compounded GLP-1 prescriptions rise despite FDA enforcement, PeptideSciences goes dark, and Cleveland Clinic finds most patients avoid dramatic weight regain.
Read digest →